Clinical Trial Update: SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for SU5416 (Semaxanib) in patients with recurrent astrocytoma or mixed glioma after radiation failure; the Phase 1/2 study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioma

Drugs mentioned

• Semaxanib (SU5416)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: COMPLETED